Full-Time

Senior Director of Biostatistics

Confirmed live in the last 24 hours

Formation Bio

Formation Bio

51-200 employees

Accelerates drug development using AI technology

Compensation Overview

$262k - $340k/yr

+ Equity + Comprehensive Benefits + Generous Perks + Hybrid Flexibility

Expert

Boston, MA, USA + 3 more

More locations: San Francisco, CA, USA | New York, NY, USA | Research Triangle, Durham, NC, USA

Candidates must reside in or be willing to relocate to New York City, Boston metro area, Research Triangle (NC), or San Francisco Bay Area.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
SAS
R
Machine Learning
Google Cloud Platform
Requirements
  • Ph.D. in Biostatistics, Statistics, or a related field with 10+ years of experience in biostatistics within the pharmaceutical or biotech industry, statistical consulting firms, or CROs supporting clinical development.
  • Proven experience leading biostatistics teams and strategies within clinical development.
  • Deep expertise in statistical trial designs, adaptive designs, Bayesian methods, and simulation-based approaches for both early and late-stage development.
  • Strong understanding of regulatory guidelines for drug development, including FDA and EMA requirements for statistical practice, regulatory submissions, and health authority interactions.
  • Experience in quantitative decision-making frameworks to support internal Go/No-Go decisions.
  • Demonstrated track record of leading statistical contributions to progress assets from diligence, early development through regulatory submissions and approvals.
  • Ability to collaborate cross-functionally with Clinical, Data Management, Programming, Data Science, Regulatory, and other teams.
  • Strong problem-solving skills with the ability to balance scientific rigor with operational efficiency.
  • Excellent communication skills, with the ability to convey complex statistical concepts into actionable insights for non-statisticians, senior management, and regulatory agencies.
  • Proficiency in SAS, R (S-Plus), and statistical software for sample size calculations (e.g., East, PASS, NQuery). Expert R programming skills are a plus.
  • Passion for innovation, AI-driven methodologies, and data-driven decision-making in clinical development.
Responsibilities
  • Lead and develop the Biostatistics team, fostering a high-performance culture aligned with Formation Bio’s mission and values. Provide mentorship and career development to ensure team growth and expertise.
  • Drive statistical strategy across clinical development programs, incorporating optimal trial designs, simulation-based approaches, and AI/ML applications to enhance efficiency and decision-making. Guide clinical and regulatory strategies to optimize trial design and maximize the probability of success.
  • Provide expert statistical input into clinical study design, endpoint selection, analysis planning, and regulatory interactions. Explore innovative trial design options to identify the most effective clinical development strategy that aligns with business needs and optimizes decision-making. Ensure study designs are scientifically rigorous, operationally feasible, and aligned with regulatory expectations. Leverage AI-driven clinical trial automation to enhance study execution, optimize resource allocation, and improve trial efficiency.
  • Partner with Clinical, Data Science, Regulatory, and Business Development teams to support drug diligence, development and regulatory interactions, FDA briefing books, and submission-related activities. Represent Biostatistics in key regulatory meetings (e.g., FDA, EMA) to ensure statistical rigor in clinical development plans.
  • Establish and refine statistical workflows, SOPs, and best practices to improve efficiency, quality control, and compliance with industry standards.
  • Champion data-driven approaches and quantitative decision-making frameworks, integrating scenario analyses and statistical trial simulations to optimize clinical trial execution and strategic development plans.
  • Stay at the forefront of industry trends and regulatory expectations, representing Formation Bio in scientific discussions, conferences, and collaborations.
  • Oversee and manage statistical vendors, including consulting statisticians and CROs, ensuring high-quality statistical deliverables and compliance with GCP and regulatory standards.

Formation Bio focuses on speeding up the process of developing new drugs by using its own AI-driven platform. This platform helps the company identify and work with clinical-stage assets, which are drugs that are already in testing phases. By acquiring these assets and using flexible financing options, Formation Bio aims to lower the high costs and long timelines usually involved in bringing new medications to market. The company primarily serves pharmaceutical and biotech firms that want to make their drug development processes faster and more efficient. What sets Formation Bio apart from its competitors is its emphasis on using advanced AI tools to improve drug selection and development, with the goal of making treatments more accessible and affordable for patients.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • $372M Series D funding boosts platform expansion and asset acquisition capabilities.
  • Collaboration with OpenAI and Sanofi advances AI-driven drug discovery standards.
  • Precision genomics partnership with SomaLogic improves biomarker identification and patient stratification.

What critics are saying

  • Competition from other AI-driven drug developers may impact market share.
  • Regulatory scrutiny on AI processes could lead to delays and compliance costs.
  • Dependence on partnerships poses risks if collaborations dissolve or underperform.

What makes Formation Bio unique

  • Formation Bio uses AI to accelerate drug development, reducing costs and timelines.
  • The company acquires clinical-stage assets, enhancing drug development flexibility and efficiency.
  • Partnerships with major pharma firms provide access to proprietary data and resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Intelligence360
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

Finsmes
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

Hit Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities

PR Newswire
Jan 10th, 2022
Trialspark partners with SomaLogic, Inc.

TrialSpark is also partnering with industry leaders such as SomaLogic to leverage precision genomics and proteomics platforms to identify key biomarkers and stratify patients using synovial fluid samples from prior clinical studies using AI and machine-learning approaches.

CB Insights
Oct 5th, 2021
Trialspark partnered with SANOFI PASTEUR on Aug 6th 18'.

TrialSpark has collaborated with pharma companies such as Sanofi, Novartis, and Pfizer, among others.